Area of research
Hematology · Genetics
Research interest
Research interests include Acute Myeloid Leukemia Research, Chronic Myeloid Leukemia Treatments, Chronic Lymphocytic Leukemia Research, and Hematopoietic Stem Cell Transplantation.
Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of <i>FLT3</i>
Devimistat plus chemotherapy vs chemotherapy alone for older relapsed or refractory patients with AML: results of the ARMADA trial
Enasidenib vs conventional care in older patients with late-stage mutant-<i>IDH2</i> relapsed/refractory AML: a randomized phase 3 trial
Omidubicel vs standard myeloablative umbilical cord blood transplantation: results of a phase 3 randomized study
A 2:1 randomized, open-label, phase II study of selinexor vs. physician’s choice in older patients with relapsed or refractory acute myeloid leukemia
Comparison of myeloid neoplasms with nonclassic 3q26.2/<scp><i>MECOM</i></scp> versus classic inv(3)/<scp><i>t</i></scp>(3;3) rearrangements reveals diverse clinicopathologic features, genetic profiles, and molecular mechanisms of <scp><i>MECOM</i></scp> activation
Open-Label Phase II Prospective, Randomized, Controlled Study of Romyelocel-L Myeloid Progenitor Cells to Reduce Infection During Induction Chemotherapy for Acute Myeloid Leukemia
Impact of race on outcomes in intermediate-risk acute myeloid leukemia
A phase 1/2 study of the oral FLT3 inhibitor pexidartinib in relapsed/refractory FLT3-ITD–mutant acute myeloid leukemia
Aurora Kinase A Inhibition Provides Clinical Benefit, Normalizes Megakaryocytes, and Reduces Bone Marrow Fibrosis in Patients with Myelofibrosis: A Phase I Trial
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia
FOXM1 contributes to treatment failure in acute myeloid leukemia
Alisertib (MLN8237), an Oral Selective Inhibitor of Aurora Kinase a, Has Clinical Activity and Restores GATA1 Expression in Patients with Myelofibrosis
NCCN Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2017
Acute Lymphoblastic Leukemia, Version 2.2015
Myelodysplastic Syndromes, Version 2.2015
The Peptidic CXCR4 Antagonist, BL-8040, Significantly Reduces Bone Marrow Immature Leukemia Progenitors By Inducing Differentiation, Apoptosis and Mobilization: Results of the Dose Escalation Clinical Trial in Acute Myeloid Leukemia
Administration of ATRA to newly diagnosed patients with acute promyelocytic leukemia is delayed contributing to early hemorrhagic death
Acute Lymphoblastic Leukemia